Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer

PHASE3CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Duodenal Ulcer
Interventions
DRUG

TAK-438

TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.

DRUG

Placebo

Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.

DRUG

Lansoprazole

Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.

DRUG

Placebo

TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.

Trial Locations (64)

Unknown

Toyota-shi

Kamagaya-shi

Kisarazu-shi

Fukui-shi

Fukuoka

Kitakyushu-shi

Kurume-shi

Onga-gun

Tagawa-shi

Yanagawa-shi

Yukuhashi-shi

Sappori-shi

Kobe

Nishinomiya-shi

Takarazuka-shi

Hitachi-shi

Hitacinaka-shi

Marugame-shi

Takamatsu

Kagoshima

Kanoya-shi

Kawasaki-shi

Yokohama

Kumamoto

Yashiro-shi

Kyoto

Nagasaki

Sasebo-shi

Ōita

Okayama

Shimajiri-gun

Daito-shi

Fujiidera-shi

Hirakata-shi

Kishiwada-shi

Osaka

Sakai-shi

Suita-shi

Takatsuki-shi

Toyonaka-shi

Saga

Ageo-shi

Kumagaya-shi

Tokorozawa-shi

Ōtsu

Shizuoka

Ashikaga-shi

Otawara-shi

Shimotsuga-gun

Shimotsuke-shi

Tokushima

Hachioji-shi

Kodaira-shi

Kokubunji-shi

Meguro-ku

Minato-ku

Mitaka-shi

Ōta-ku

Setagaya-ku

Shinagawa-ku

Wakayama

Yamagata

Shimonoseki-shi

Kofu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY